Medical Therapy for Obesity in Italy
Evidence-Based Medical Therapy for Chronic Weight Management
Obesity is a chronic, progressive and relapsing disease characterized by excess or dysfunctional adipose tissue and associated with increased morbidity and mortality. It is not merely a lifestyle condition, but a complex medical disorder influenced by genetic, neuroendocrine, metabolic and environmental factors.
According to international scientific societies — including the European Association for the Study of Obesity (EASO), the American Association of Clinical Endocrinology (AACE) and the American Diabetes Association (ADA) — obesity requires structured, long-term medical management comparable to other chronic diseases.
Pharmacological therapy represents a central component of modern obesity treatment when lifestyle intervention alone is insufficient.
Evidence-based GLP-1–based therapy and other pharmacological treatments are available in Italy under specialist supervision. Consultations are offered in person in the Milan and Padua area, as well as via secure telemedicine for international patients seeking medically supervised weight management.
Indications for Pharmacological Treatment
International guidelines recommend considering anti-obesity medication in:
Patients with BMI ≥ 30 kg/m²
Patients with BMI ≥ 27 kg/m² with obesity-related comorbidities (type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, NAFLD)
Patients with clinically significant weight regain after previous weight loss
Individuals requiring preoperative metabolic optimization before bariatric surgery
Treatment decisions are individualized and based on a comprehensive clinical evaluation.
Mechanisms of Action of Modern Anti-Obesity Medications
Recent pharmacological advances have significantly improved the efficacy of medical weight management.
Current evidence-based options include:
GLP-1 receptor agonists (e.g., semaglutide)
Dual GIP/GLP-1 receptor agonists (e.g., tirzepatide)
Other approved agents according to European and international regulatory frameworks
These medications act primarily through:
Central appetite regulation at the hypothalamic level
Delayed gastric emptying
Enhanced satiety signaling
Improvement in glycemic control
Reduction of visceral adiposity
Clinical trials have demonstrated substantial and sustained weight reduction, with additional benefits on cardiometabolic risk factors.
Comprehensive Medical Assessment
Before initiating pharmacological therapy, patients undergo:
Detailed medical history and physical examination
Evaluation of obesity-related complications
Metabolic and hormonal assessment
Body composition analysis (when appropriate)
Cardiovascular risk stratification
Review of previous weight-loss interventions
This assessment allows risk-benefit evaluation and selection of the most appropriate therapeutic strategy.
Integration Within a Multidisciplinary Model
Pharmacological treatment is not a stand-alone intervention.
Consistent with EASO and IFSO recommendations, optimal outcomes are achieved through a structured multidisciplinary approach including:
Medical supervision
Nutritional counseling
Physical activity prescription
Psychological support when indicated
Continuous monitoring and follow-up
Obesity management requires long-term care, and discontinuation of therapy without appropriate maintenance strategies may lead to weight regain.
Monitoring, Safety and Long-Term Management
Anti-obesity medications require:
Gradual dose titration
Monitoring of tolerability and side effects
Periodic metabolic reassessment
Evaluation of therapeutic response
Therapy is adjusted according to clinical evolution and patient-specific goals.
Regular follow-up can be performed in person or via telemedicine, ensuring continuity of care.
Relationship with Bariatric and Endoscopic Treatment
Pharmacological therapy may be indicated:
As a primary treatment in eligible patients
As bridge therapy before bariatric surgery
In patients not eligible or unwilling to undergo surgery
In cases of post-surgical weight regain
Medical, endoscopic and surgical strategies are complementary tools within a comprehensive obesity treatment pathway.
A Chronic Disease Model of Care
Obesity should be approached as a chronic disease requiring:
Long-term therapeutic planning
Evidence-based interventions
Continuous medical supervision
The goal of treatment is not only weight reduction, but improvement in metabolic health, reduction of cardiovascular risk and enhancement of quality of life.
Obesity treatment in Italy for international patients
For international patients seeking specialized obesity treatment in Italy, a structured and personalized pathway is available.
Medical consultations can be conducted in English, both in person and via telemedicine. When appropriate, pharmacological therapy can be integrated with advanced metabolic assessment, multidisciplinary follow-up, and, if indicated, bariatric or endoscopic procedures within accredited clinical facilities.
For patients traveling to Italy, treatment planning can be coordinated in advance to ensure:
Comprehensive initial medical evaluation
Personalized therapeutic strategy
Integration with nutritional and metabolic support
Structured follow-up plan after returning home
Italy offers a high standard of medical care within a regulated European healthcare framework. The goal is to provide evidence-based treatment in a professional, discreet and patient-centered environment.
Integrated Medical Stay Program at Hotel Terme Quisisana
For selected patients, medical therapy for obesity can be integrated within a structured medical stay in collaboration with Hotel Terme Quisisana, a historic thermal hotel in Abano Terme renowned for its wellness and rehabilitation facilities.
This model is particularly suitable for international patients who wish to combine high-level medical supervision with a comfortable and discreet residential setting.
The program allows an intensive initial phase in a controlled environment, facilitating therapeutic adherence, metabolic optimization and structured lifestyle implementation.
Clinical Integration During the Stay
The integrated pathway may include:
Specialist medical consultation and metabolic evaluation
Pharmacological obesity treatment, including GLP-1–based therapy when indicated
Body composition assessment
Personalized nutritional planning
Supervised physical activity sessions within the hotel gym facilities
Sleep evaluation when clinically indicated, including assessment for obstructive sleep apnea
Structured therapeutic planning prior to discharge
The collaboration enables close coordination between medical assessment and lifestyle intervention, ensuring that pharmacological therapy is embedded within a comprehensive and multidisciplinary clinical framework.
Book a Consultation
If you are considering medical therapy for obesity or GLP-1–based treatment, a comprehensive medical assessment is the first step.
Each treatment plan is individualized, based on clinical evaluation, metabolic profile and long-term health objectives.
International patients are welcome to schedule an initial consultation — in person or via telemedicine — to discuss eligibility, expected outcomes and the most appropriate therapeutic pathway.
A structured, evidence-based and medically supervised approach is essential for safe and sustainable weight management.
You can schedule your appointment here.